Table 5.
Everolimus exposure within one dosing interval of approximately 24 h according to dose and to treatment period (results of individual post‐hoc estimates based on the population pharmacokinetic model)
| Parameter | Day of everolimus treatment | 2.5 mg QD | 5 mg QD | 7.5 mg QD | 10 mg QD |
|---|---|---|---|---|---|
| AUCτ (h* ng/mL blood) | Days 1‐10 (scheduled: day 5) | (n = 4) 115 (1.48) | (n = 3) 284 (1.46) | (n = 19) 451 (1.79) | (n = 3) 302 (1.59) |
| Days 11‐20 (scheduled: day 14) | (n = 3) 121 (1.71) | (n = 2) 152 (1.05) | (n = 6) 241 (1.37) | (n = 4) 349 (1.88) | |
| After Day 29 (scheduled: day 29, with sorafenib) | (n = 3) 69 (1.68) | (n = 2) 137 (1.12) | (n = 6) 287 (1.91) | (n = 3) 240 (1.36) |
Values are given as geometric mean (coefficient of variation). Numbers of patients (n) vary because not for all patients samples were available in all periods.